Efficacy, toxicity and nursing of paclitaxel combined with cisplatin in the treatment of recurrent cervical cancer
10.3760/cma.j.cn121382-20220216-00406
- VernacularTitle:顺铂联合紫杉醇治疗复发宫颈癌的效果观察、毒性反应及护理
- Author:
Yunzi LIU
1
Author Information
1. 天津医科大学第二医院妇科，天津 300211
- Keywords:
Paclitaxel;
Cisplatin;
Recurrent cervical cancer;
Chemotherapy;
Nursing
- From:
International Journal of Biomedical Engineering
2022;45(4):317-320
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore and evaluate the effect of clinical toxicity nursing on the therapeutic effect of paclitaxel combined with cisplatin in the treatment of recurrent cervical cancer.Methods:Sixty patients with recurrent cervical cancer treated in the Second Hospital of Tianjin Medical University from May 2017 to May 2019 were randomly divided into two groups. The control group was given paclitaxel chemotherapy and routine nursing, and the study group was given paclitaxel combined with cisplatin and clinical toxicity nursing.Results:In the study group, the total effective rate of 93.3% was significantly higher than that of 73.3% in the control group ( P<0.05), and the levels of inflammatory indexes, including C-reactive protein (CRP), interleukin-6 (IL-6), white blood cell (WBC) and erythrocyte sedimentation rate (ESR) in the study group were lower than those in the control group ( P<0.05). The incidence of toxicity in the study group was 10.0% lower than that in the control group(36.7%, P<0.05). Conclusions:The use of paclitaxel combined with cisplatin chemotherapy for recurrent cervical cancer and clinical toxic reaction nursing can improve the effectiveness rate of treatment, reduce the levels of various inflammatory indicators, and reduce the incidence of toxic reactions with high safety, thus prolonging the survival time of patients, making it worthy of clinical application.
